Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Resistance to Azacitidine Is Determined at Cellular Level By Lower Expression of Nucleoside Metabolizing Enzymes

Erico Masala, Ana Belén Valencia, Alessandro Sanna, MD, Alice Brogi, Laila Zaroili, Valeria Santini, MD

Blood (2016) 128 (22): 5129.

https://doi.org/10.1182/blood.V128.22.5129.5129

Published: 2016

Journal Articles

Hypoxia Increases Repopulating Ability of Myelodysplastic Syndrome Bone Marrow Cells

Erico Masala, Francesca Buchi, Serena Pillozzi, Ana Valencia-Martinez, Tommaso Rondelli, Antonella Gozzini, MD, Alessandro Sanna, MD, Alberto Bosi, Persio Dello Sbarba, Valeria Santini, MD

Blood (2015) 126 (23): 4753.

https://doi.org/10.1182/blood.V126.23.4753.4753

Published: 2015

Journal Articles

The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism

Blood (2013) 122 (21): 2761.

https://doi.org/10.1182/blood.V122.21.2761.2761

Published: 2013

Journal Articles

High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry

Blood (2012) 120 (21): 1702.

https://doi.org/10.1182/blood.V120.21.1702.1702

Published: 2012

Journal Articles

ANTI-Leukemic Activity of DNA Methyltransferase Inhibitors Azacitidine and Decitabine On AML1-ETO Positive CELLS Is Evident At LOW Doses and Selectively Mediated by Epigenetic Mechanisms

Francesca Buchi, Elena Spinelli, Erico Masala, Ana Valencia, PhD, Alessandro Sanna, MD, Antonella Gozzini, MD, Valeria Santini, MD

Blood (2012) 120 (21): 4615.

https://doi.org/10.1182/blood.V120.21.4615.4615

Published: 2012

Journal Articles

Severe Hypoxia Promotes Selection of Repopulating Progenitor CELLS in Primary MDS BONE Marrow CELL Culture

Erico Masala, Francesca Buchi, Ana Valencia, PhD, Antonella Gozzini, MD, Alessandro Sanna, MD, Alberto Bosi, MD, Persio Dello Sbarba, Valeria Santini, MD

Blood (2012) 120 (21): 4747.

https://doi.org/10.1182/blood.V120.21.4747.4747

Published: 2012

Journal Articles

Mechanism of Resistance to Azacitidine in Myelodisplastic Syndromes.

Ana Belen Valencia Martinez, PhD, Alessandro Martino, PhD, Francesca Buchi, Erico Masala, Alessandro Sanna, MD, Federico Canzian, Daniela Cilloni, MD, Valentina Gaidano, MD, Antonella Gozzini, Alberto Bosi, MD, Valeria Santini, MD

Blood (2012) 120 (21): 2810.

https://doi.org/10.1182/blood.V120.21.2810.2810

Published: 2012

Journal Articles

Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM).

Blood (2012) 120 (21): 2814.

https://doi.org/10.1182/blood.V120.21.2814.2814

Published: 2012

Journal Articles

An Observational Multicenter Study to Assess the Cost of Illness and Quality of Life in Patients with Myelodysplastic Syndromes in Italy

Valeria Santini, MD, Alessandro Sanna, MD, Alberto Bosi, MD, Giuliana Alimena, MD, Giuseppina Loglisci, MD, Alessandro Levis, MD, Flavia Salvi, MD, Carlo Finelli, MD, Cristina Clissa, MD, Giorgina Specchia, MD, Alessandra Ricco, MD, Agostino Cortelezzi, MD, Valeria Ferla, MD, Mariarita Sciumé, MD, Francesco Nobile, MD, Esther Oliva, MD, Carlo Lazzaro, EconD, Elisa Martelli, MSc

Blood (2011) 118 (21): 1023.

https://doi.org/10.1182/blood.V118.21.1023.1023

Published: 2011

Journal Articles

Treatment with Erythropoietic Stimulating Agents in IPSS Lower Risk MDS: Outcome Comparison Between 5q- and Non 5q- MDS Cases

Alessandro Sanna, MD, Roberto Latagliata, Daniela Gioia, Antonella Gozzini, MD, Francesca Sassolini, MD, Giuliana Alimena, MD, Alessandro Levis, MD, Alberto Bosi, MD, Valeria Santini, MD

Blood (2011) 118 (21): 2799.

https://doi.org/10.1182/blood.V118.21.2799.2799

Published: 2011

Journal Articles

Decitabine Treatment in Higher Risk MDS, CMML and AML Post-MDS Who Failed Azacitidine

Alessandro Sanna, MD, Antonella Gozzini, MD, Francesca Sassolini, MD, Alberto Bosi, MD, Valeria Santini, MD

Blood (2011) 118 (21): 5052.

https://doi.org/10.1182/blood.V118.21.5052.5052

Published: 2011

Journal Articles

Comorbidities Indexes In Patients Treated with 5-Azacitidine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation

Alessandro Sanna, MD, Laura Cannella, MD, Antonella Gozzini, MD, Massimo Breccia, MD, Francesca Sassolini, MD, Alberto Bosi, MD, Giuliana Alimena, MD, Valeria Santini, MD

Blood (2010) 116 (21): 606.

https://doi.org/10.1182/blood.V116.21.606.606

Published: 2010

Journal Articles

Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes

Valeria Santini, MD, Domenico Girelli, MD, Alessandro Sanna, MD, Nicola Martinelli, MD, Lorena Duca, Natascia Campostrini, PhD, Agostino Cortelezzi, PhD, Michela Corbella, PhD, Alberto Bosi, PhD, Gianluigi Reda, Maria Domenica Cappellini, MD

Blood (2010) 116 (21): 4250.

https://doi.org/10.1182/blood.V116.21.4250.4250

Published: 2010

Journal Articles

Iron Metabolism and Erythropoietic Stress in Myelodysplastic Syndromes.

Valeria Santini, MD, Alessandro Sanna, MD, Lorena Duca, Antonella Gozzini, MD, Domenico Girelli, MD, PhD, Agostino Cortelezzi, MD, Gianluigi Reda, MD, Natascia Campostrini, Maria Domenica Cappellini, MD

Blood (2009) 114 (22): 1752.

https://doi.org/10.1182/blood.V114.22.1752.1752

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Resistance to Azacitidine Is Determined at Cellular Level By Lower Expression of Nucleoside Metabolizing Enzymes

Hypoxia Increases Repopulating Ability of Myelodysplastic Syndrome Bone Marrow Cells

The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism

High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry

ANTI-Leukemic Activity of DNA Methyltransferase Inhibitors Azacitidine and Decitabine On AML1-ETO Positive CELLS Is Evident At LOW Doses and Selectively Mediated by Epigenetic Mechanisms

Severe Hypoxia Promotes Selection of Repopulating Progenitor CELLS in Primary MDS BONE Marrow CELL Culture

Mechanism of Resistance to Azacitidine in Myelodisplastic Syndromes.

Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM).

An Observational Multicenter Study to Assess the Cost of Illness and Quality of Life in Patients with Myelodysplastic Syndromes in Italy

Treatment with Erythropoietic Stimulating Agents in IPSS Lower Risk MDS: Outcome Comparison Between 5q- and Non 5q- MDS Cases

Decitabine Treatment in Higher Risk MDS, CMML and AML Post-MDS Who Failed Azacitidine

Comorbidities Indexes In Patients Treated with 5-Azacitidine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation

Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes

Iron Metabolism and Erythropoietic Stress in Myelodysplastic Syndromes.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only